
## **Catherine Tomaro-Duchesneau**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/388256/publications.pdf Version: 2024-02-01



CATHERINE

| #  | Article   | IF  | CITATIONS |
|----|---|-----|-----------|
| 1  | Microencapsulated <i>Bifidobacterium longum</i> subsp. <i>infantis</i> ATCC 15697 Favorably<br>Modulates Gut Microbiota and Reduces Circulating Endotoxins in F344 Rats. BioMed Research<br>International, 2014, 2014, 1-11.                        | 0.9 | 2,927     |
| 2  | Polymeric nanohybrids and functionalized carbon nanotubes as drug delivery carriers for cancer therapy. Advanced Drug Delivery Reviews, 2011, 63, 1340-1351.  | 6.6 | 226       |
| 3  | Gut microbiota: next frontier in understanding human health and development of biotherapeutics.<br>Biologics: Targets and Therapy, 2011, 5, 71.   | 3.0 | 181       |
| 4  | Synthesis of TAT peptide-tagged PEGylated chitosan nanoparticles for siRNA delivery targeting neurodegenerative diseases. Biomaterials, 2013, 34, 1270-1280.  | 5.7 | 161       |
| 5  | Cholesterol lowering with bile salt hydrolase-active probiotic bacteria, mechanism of action, clinical evidence, and future direction for heart health applications. Expert Opinion on Biological Therapy, 2013, 13, 631-642.                       | 1.4 | 140       |
| 6  | Effect of Probiotics Lactobacillus and Bifidobacterium on Gut-Derived Lipopolysaccharides and<br>Inflammatory Cytokines: An In Vitro Study Using a Human Colonic Microbiota Model. Journal of<br>Microbiology and Biotechnology, 2013, 23, 518-526. | 0.9 | 129       |
| 7  | Probiotics in colorectal cancer (CRC) with emphasis on mechanisms of action and current perspectives. Journal of Medical Microbiology, 2013, 62, 1107-1123.   | 0.7 | 118       |
| 8  | Cholesterol Assimilation by <i>Lactobacillus</i> Probiotic Bacteria: An <i>In Vitro</i> Investigation.<br>BioMed Research International, 2014, 2014, 1-9.   | 0.9 | 103       |
| 9  | The Gut Microbiota and Human Health with an Emphasis on the Use of Microencapsulated Bacterial<br>Cells. Journal of Biomedicine and Biotechnology, 2011, 2011, 1-12.  | 3.0 | 71        |
| 10 | A novel method for synthesizing PEGylated chitosan nanoparticles: strategy, preparation, and in vitro<br>analysis. International Journal of Nanomedicine, 2011, 6, 485.   | 3.3 | 61        |
| 11 | Development and characterization of chitosan-PEG-TAT nanoparticles for the intracellular delivery of siRNA. International Journal of Nanomedicine, 2013, 8, 2041.   | 3.3 | 60        |
| 12 | Human Intestinal Enteroids With Inducible Neurogenin-3 Expression as a Novel Model of Gut Hormone<br>Secretion. Cellular and Molecular Gastroenterology and Hepatology, 2019, 8, 209-229.   | 2.3 | 60        |
| 13 | Effect of orally administered L. fermentum NCIMB 5221 on markers of metabolic syndrome: an in vivo analysis using ZDF rats. Applied Microbiology and Biotechnology, 2014, 98, 115-126.  | 1.7 | 57        |
| 14 | Probiotic Ferulic Acid Esterase Active Lactobacillus fermentum NCIMB 5221 APA Microcapsules for<br>Oral Delivery: Preparation and in Vitro Characterization. Pharmaceuticals, 2012, 5, 236-248.   | 1.7 | 53        |
| 15 | The gut microbiome, probiotics, bile acids axis, and human health. Trends in Microbiology, 2014, 22, 306-308.   | 3.5 | 53        |
| 16 | <b>Probiotics as oral health biotherapeutics</b> . Expert Opinion on Biological Therapy, 2012, 12, 1207-1220.   | 1.4 | 48        |
| 17 | Microencapsulation for the Therapeutic Delivery of Drugs, Live Mammalian and Bacterial Cells, and<br>Other Biopharmaceutics: Current Status and Future Directions. Journal of Pharmaceutics, 2013, 2013,<br>1-19.                                   | 4.6 | 40        |
| 18 | Oral Probiotic Microcapsule Formulation Ameliorates Non-Alcoholic Fatty Liver Disease in Bio F1B<br>Golden Syrian Hamsters. PLoS ONE, 2013, 8, e58394.  | 1.1 | 38        |

CATHERINE

| #  | Article  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Novel probiotic dissolvable carboxymethyl cellulose films as oral health biotherapeutics: <i>in vitro</i> preparation and characterization. Expert Opinion on Drug Delivery, 2013, 10, 1471-1482.  | 2.4 | 36        |
| 20 | Investigation of probiotic bacteria as dental caries and periodontal disease biotherapeutics. Beneficial Microbes, 2014, 5, 447-460.   | 1.0 | 27        |
| 21 | Probiotics for the Prevention and Treatment of Allergies, with an Emphasis on Mode of Delivery and<br>Mechanism of Action. Current Pharmaceutical Design, 2014, 20, 1025-1037.   | 0.9 | 26        |
| 22 | Systemic siRNA Delivery via Peptide-Tagged Polymeric Nanoparticles, Targeting PLK1 Gene in a Mouse<br>Xenograft Model of Colorectal Cancer. International Journal of Biomaterials, 2013, 2013, 1-13.   | 1.1 | 23        |
| 23 | Transit Time Affects the Community Stability of <i>Lactobacillus</i> and <i>Bifidobacterium</i> Species<br>in an <i>In Vitro</i> Model of Human Colonic Microbiotia. Artificial Cells, Blood Substitutes, and<br>Biotechnology, 2011, 39, 351-356.   | 0.9 | 22        |
| 24 | Discovery of a bacterial peptide as a modulator of GLP-1 and metabolic disease. Scientific Reports, 2020, 10, 4922.  | 1.6 | 22        |
| 25 | Intranasal, siRNA Delivery to the Brain by TAT/MGF Tagged PEGylated Chitosan Nanoparticles. Journal of Pharmaceutics, 2013, 2013, 1-10.  | 4.6 | 20        |
| 26 | Lactobacillus fermentum NCIMB 5221 and NCIMB 2797 as cholesterol-lowering probiotic biotherapeutics: in vitro analysis. Beneficial Microbes, 2015, 6, 861-869.   | 1.0 | 17        |
| 27 | Degradation of the Incretin Hormone Glucagon-Like Peptide-1 (GLP-1) by Enterococcus faecalis<br>Metalloprotease GelE. MSphere, 2020, 5, .  | 1.3 | 14        |
| 28 | Intranasal Delivery of Chitosan–siRNA Nanoparticle Formulation to the Brain. Methods in Molecular<br>Biology, 2014, 1141, 233-247.   | 0.4 | 12        |
| 29 | Design of a novel gut bacterial adhesion model for probiotic applications. Artificial Cells,<br>Nanomedicine and Biotechnology, 2013, 41, 116-124.   | 1.9 | 9         |
| 30 | Enrichment ofBifidobacterium longumsubsp.infantisATCC 15697 within the human gut microbiota<br>using alginate-poly-l-lysine-alginate microencapsulation oral delivery system: anin vitroanalysis using<br>a computer-controlled dynamic human gastrointestinal model. Journal of Microencapsulation, 2014,<br>31, 230-238. | 1.2 | 6         |
| 31 | 866: Screening of Lactobacillus reuteri strains for their short chain fatty acids production, stability and potential in colorectal cancer: In-vitro analysis. European Journal of Cancer, 2014, 50, S212.   | 1.3 | 1         |